Lexicon Pharma (LXRX) Announces COO Departuree

On September 13, 2024, Lexicon Pharma (NASDAQ: LXRX) and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Honeywell shuffles leadership in process and building units
• CVS Health and Aetna Help Florida City Families Prepare for the School Year at Branches' Back to School Night